| Autor: |
HIROAKI SOYAMA, MASASHI TAKANO, MORIKAZU MIYAMOTO, TOMOYUKI YOSHIKAWA, TADASHI AOYAMA, TOMOKO GOTO, JUNKO HIRATA, AYAKO SUZUKI, HIDENORI SASA, KENICHI FURUYA |
| Předmět: |
|
| Zdroj: |
Molecular & Clinical Oncology; 2017, Vol. 7 Issue 1, p42-46, 5p |
| Abstrakt: |
The aim of the present study was to identify clinicopathological factors in long-erm survivors following ovarian cancer recurrence. The patients who achieved longer survival after recurrence (n=18) and those who succumbed to the disease earlier (n=47) were identified and analyzed. There were no significant differences in age, performance status, stage distribution or histology between the two groups. Additionally, no significant difference was observed in progression-ree survival after primary therapy. Multivariate analyses revealed that the predictive factors for long-term survival were i) secondary debulking surgery (OR=13.3; 95% CI: 1.39-226.7), ii) favourable response rate of second-line chemotherapy (OR=46.5; 95% CI: 1.84-313-4), and iii) ≥3 regimens after first recurrence (OR=9.01; 95% CI: 1.28-117.7). This study revealed that prolonged post-progression survival was associated with post-recurrence treatment. Therefore, appropriate selection of secondary debulking surgery and better chemotherapeutic response may lead to prolonged post-progression survival in recurrent ovarian cancer patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
